Labor Relations
The area of the plant is 11 hectares. The number of employees is more than 2,700 people. The plant produces approximately 200 types of medicines from 12 pharmacotherapeutic groups - generics. And it constantly replenishes the list of its products - every year with at least 10 of the most popular drugs. More than 5 billion tablets, 500 million ampoules, 90 million capsules, 20 million bottles of antibiotics in sterile powders, 13 million tubes of ointments and gels produced by the plant annually improve the health of people in many countries around the world.
The volume of industrial production in actual prices for 2014 amounted to 1100.0 billion rubles. (equivalent - 111.1 million US dollars). Medicines produced by BZMP OJSC are supplied on a regular basis not only to the neighboring Russian Federation and Ukraine, but also to Azerbaijan, Armenia, Afghanistan, Vietnam, Georgia, Egypt, Iraq, Yemen, Kazakhstan, North Korea, Kyrgyzstan, Latvia, Lebanon, Lithuania , Macedonia, Moldova, Uzbekistan, Somalia, USA, Tajikistan, Turkmenistan, Estonia. The plant plans to significantly expand its sales geography in the very near future: to develop the markets of South America, Africa, and Asian countries. This is facilitated by the active implementation of the GMP quality system at the enterprise. For impressive export volumes, Open Joint Stock Company "Borisov Plant" medical supplies
"is traditionally noted as the best exporter of the year: 2008, 2010, 2012, 2013, 2014. Every year the plant increases the volume of export products: on average for the period 2011-2014 - by 8%.
The open joint-stock company “Borisov Medical Preparations Plant” relies on constant development and modernization: 300 production technologies already mastered by the enterprise are supplemented with new ones, the equipment fleet is regularly updated, and production is consistently certified for compliance with GMP standards.
It is worth noting that the priority market for the Borisov Medical Preparations Plant Open Joint Stock Company remains Belarus. Providing the country's population with high-quality, effective, affordable medicines is one of the strategic directions activities of the enterprise.
Modern equipment, the latest technologies, the most precise methods of product quality control, qualified personnel - all these conditions determine the fact that tens of millions of people in many countries around the world rightfully trust the Borisov Medical Preparations Plant Open Joint Stock Company with their most valuable thing - their health.
Video presentation of the company:
Actual and legal address:
222518, Republic of Belarus,
Minsk region, Borisov,
Chapaeva st. 64
The “hotline” is conducted by the organization’s specialists on issues relevant to citizens and legal entities once a quarter, on the 2nd Tuesday of the last month of the quarter from 8.00 to 8.30.
"Straight phone line" carried out by the General Director, Chief Engineer, Deputy General Directors on issues relevant to citizens and legal entities - Once a quarter, 2nd Tuesday of the last month of the quarter from 8.00 to 8.30.
| Job title | Full Name | Phone number |
| CEO | Fando Alexander Nikolaevich | 8 0177 73 22 61 |
| Chief Engineer | Deresh Vitaly Vasilievich | 8 0177 76 64 51 |
| Deputy General Director for Commercial Affairs | Lopatenko Vladimir Alekseevich | 8 0177 73 42 62 |
| Deputy General Director for Economics | Satsuk Larisa Adamovna | 8 0177 74 43 67 |
| Deputy General Director for Quality - Head of QC | Baturo Tatyana Vasilievna | 8 0177 74 43 86 |
| Deputy General Director for Ideology, Personnel and Social Issues. | Kovaleva Natalya Leonidovna | 8 0177 73 78 07 |
Characteristics of OJSC "Borisov Plant of Medical Preparations"
The object of research in course work is an open joint-stock company "Borisov Medical Preparations Plant" - a modern, dynamically developing enterprise in the pharmaceutical industry, which, in accordance with the needs of the population, the demands of healthcare and the pharmaceutical market, is increasing the range and volume of drugs produced.
Name of the enterprise: Open joint-stock company “Borisov Medical Preparations Plant.
Industry: Production and sale of pharmaceutical and microbiological products.
Main activities and products: production and wholesale sales of medicines.
Legal address: Borisov, st. Chapaeva, 64.
Form of ownership: republican.
Registration date: 01/30/2009 decision of the Minsk Regional Executive Committee No. 5-r.
OJSC "Borisov Plant of Medical Preparations" was put into operation in 1965 as a pharmaceutical factory for the production of medicines for the needs of Belarus. In 1969, the factory was transferred to the category of enterprises of union subordination.
Currently, OJSC "Borisov Plant of Medical Preparations" is an enterprise of the Republic of Belarus, based on republican property, administered by the Belarusian State Concern for the production and sale of pharmaceutical and microbiological products.
The enterprise is an independent economic entity with the rights of a legal entity, has an independent balance sheet, a current and foreign currency account in the Borisov branch of BankBelVEB OJSC, a seal, a trademark, forms and stamps, samples of which are approved by its head. The enterprise operates on the principles of full economic accounting and can develop on mixed forms of ownership in accordance with current legislation.
The organizational structure of OJSC "Borisov Medical Preparations Plant" has a linear-functional form (Appendix A).
The management of the company is carried out in accordance with current legislation and the Charter of the company on the basis of a combination of the rights and interests of the workforce and property owners.
The governing bodies are:
- - General Meeting of Shareholders;
- - supervisory board;
- - CEO.
The powers of the management bodies are determined by the Company's Charter.
The supreme governing body is the general meeting of shareholders, which is held at least once a year. Issues at the meeting are resolved according to the principle: one share - one vote.
To carry out general management of the company's activities during the period between shareholders' meetings, a supervisory board is elected.
The executive body of the company is the general director.
All subordinate managers are subordinate to the General Director. The General Director is the main organizer of the work and effective interaction of production units, sites, and services. Combining economic and administrative methods of management, he ensures the high-quality fulfillment of tasks by the organization, all obligations to the state budget, suppliers, customers, banks, and ensures compliance with the rule of law in the activities of the enterprise.
A single vertical leadership line and a direct path of active influence on subordinates have been created. Each line manager is directly subordinate to the higher management of the organization. However, workers perform different functions, which means that there is a division of divisions based on functional characteristics, i.e. according to the specific tasks that they have to solve. Through a rigid system of connections, the smooth operation of each subsystem and the organization as a whole is ensured.
The advantage of this control structure is simplicity, reliability and cost-effectiveness. The manager in this case must cover all aspects of the enterprise's activities. Functional units carry out all the technical preparation of the organization of work, prepare options for resolving issues related to the management of the processes of preparation of the organization of work, relieve line managers from planning financial calculations, logistics and other issues.
Management functions are performed in accordance with the provisions on structural divisions, job descriptions, enterprise standards, instructions, management procedures and other documents.
Thus, the structure of the organization is based on a specialized division of labor, that is, work is not randomly distributed among people, but is assigned to specialists who are able to perform it best from the point of view of the organization as a whole.
The main advantages of the organizational structure of OJSC Borisov Medical Preparations Plant are:
- - prompt implementation of actions according to orders and instructions given by superior managers to subordinates,
- - rational combination of linear and functional relationships;
- - stability of powers and responsibility for personnel.
- - unity and clarity of management;
- - prompt decision-making and implementation;
- - personal responsibility of each manager for performance results;
- - professional problem solving by specialists of functional services.
However, the linear-functional management structure also has a number of disadvantages, such as:
- - duplication of functions of the manager and functional specialists in the process of management activities;
- - slow decision making;
- - reluctance of managers to take responsibility for decisions made;
- - the emergence of intra-production barriers that limit the scope of interest of functional units in the effective development of production;
- - disagreements between line and functional services;
- - opposition of line managers to the work of functional specialists;
- - incorrect interpretation of information transmitted to line managers by functional managers.
Thus, the noted shortcomings lie not in the plane of a specific linear organizational management structure, but in the plane of organizing the work of the enterprise, and can be eliminated by replacing some of the bureaucratic elements.
The enterprise is constantly and purposefully working to improve the management system: programs are being developed and implemented to reform the system of organization and remuneration, financial recovery, technical re-equipment of the main production and marketing research in order to generate income from other activities.
Today, the product range includes about 200 types of drugs from 11 pharmacological groups.
The main activities of the enterprise are production:
- - injection solutions in ampoules and sterile powder forms of antibiotics;
- - tablet drugs;
- - liquid phytochemicals and soft dosage forms:
- - drugs in hard gelatin capsules;
- - original preparations based on oxidized cellulose, components intellectual property enterprises.
The fundamental principle of the company's policy is to provide the population with affordable and high-quality medicines.
In accordance with this principle, the plant has chosen the main directions of its development to produce import-substituting products (generics), as well as to expand the range of original drugs that constitute the intellectual property of the enterprise, orientation and coordination of production and export policies in accordance with market requirements.
Within State program import substitution, the plant annually masters the production of modern import-substituting drugs of various pharmacotherapeutic groups, which are in no way inferior in quality to imported analogues, and at a price lower than those.
The company owns more than 300 technologies for the production of medicines. The permanent range of products includes about 200 types of drugs from 14 ATC groups of the 1st level. The leading ATC groups are J (28%) - antimicrobial drugs for systemic use, N (28%) - drugs for the treatment of the nervous system, C (11%) - drugs for the treatment of the cardiovascular system. The structure of product production for 2013 is presented in Figure 3.
Figure 3 - Structure of production in physical terms for 2013
Note - Source: own development
The volume of industrial production in actual prices for 2013 amounted to 917.3 billion rubles. (equivalent to US$103.3 million).
Medicines produced by BZMP OJSC are supplied on a regular basis not only to the neighboring Russian Federation and Ukraine, but also to Azerbaijan, Armenia, Afghanistan, Vietnam, Georgia, Egypt, Iraq, Yemen, Kazakhstan, North Korea, Kyrgyzstan, Latvia, Lebanon, Lithuania , Macedonia, Moldova, Uzbekistan, Somalia, USA, Tajikistan, Turkmenistan, Estonia. The plant plans to significantly expand its sales geography in the very near future: to develop the markets of South America, Africa, and Asian countries. This is facilitated by the active implementation of the GMP quality system at the enterprise.
For its impressive export volumes, Borisov Medical Preparations Plant OJSC has already been awarded three times as the best exporter of the year: in 2008, 2010 and 2012. Every year the plant increases the volume of export products: in 2011. - by 7.4%, in 2012 - by 10.2%, by 5.6% in 2013. The volume of product exports in 2013 amounted to 55.4 million US dollars.
The volume and share of supplies in value terms are shown in Table 1.
Table 1 - Sales markets and their share in the total volume in 2012-2013.
|
Country of supply |
|||||
|
Volume of supplies |
Volume of supplies, thousand US dollars |
Share in total supplies, % |
|||
|
thousand US dollars |
|||||
|
Belarus |
|||||
|
Kazakhstan |
|||||
|
Uzbekistan |
|||||
|
Kyrgyzstan |
|||||
|
Turkmenistan |
|||||
|
Tajikistan |
|||||
|
Azerbaijan |
|||||
|
Other (return of raw materials) |
|||||
| Open Joint Stock Company "Borisov Medical Preparations Plant" | |
|---|---|
| Type | State enterprise |
| Location | Republic of Belarus: Borisov |
| Key figures | Deresh Vitaly Vasilievich (General Director) |
| Industry | Production of medicines |
| Products | Magnecard |
| Turnover | US$131 million |
| Number of employees | 3000 |
| Website | www.borimed.com |
Open joint-stock company "Borisov Medical Preparations Plant" is a leading manufacturer and exporter of broad-spectrum medicines in the Republic of Belarus. The Borisov Medical Preparations Plant has 4 main production facilities, as well as auxiliary services (printing and cardboard shop, mechanical repair shop, power section, instrumentation and automation section, repair and construction section, transport shop with a vehicle fleet, etc.), located in Borisov, Minsk region.
The plant is an Open Joint Stock Company and is subordinate to the Republican Unitary Enterprise " Management Company Belfapmprom holding.
Medicines produced by BZMP OJSC are supplied to 24 countries of the world: CIS countries, Moldova, Georgia, USA, countries of Central and Southeast Asia, countries of the Middle East. The volume of industrial production in actual prices for 2017 amounted to 252.7 million BYN (equivalent to 131 million US dollars).
On the territory of the plant there is a Production Unitary Enterprise "Frebor" with a 100% authorized share of the capital of OJSC "BZMP", specializing in the production of disposable medical products. The product line includes more than 150 items and is divided into two categories: consumables for hemodialysis therapy and general medical products.
STORY
OJSC "BZMP" was founded in 1965. The history of the enterprise began with the organization of a small pharmaceutical factory employing 257 people. The company produced tinctures, ointments, oils and tablets.
PRODUCTION
The enterprise occupies an area of over 10 hectares, its production facilities include 5 main workshops, as well as support services. The number of employees is about 3000 people. The plant produces more than 280 types of medicines from 12 pharmacotherapeutic groups - generics:
- injection solutions in ampoules;
- powders for the preparation of injection solutions in vials;
- solid dosage forms (tablets);
- liquid phytochemicals, alcohol and oil medicines;
- soft dosage forms;
- medicines in hard gelatin capsules.
The company specializes in the production of medicines for the treatment of the following diseases:
- cardiovascular system (Magnecard®, Aspicard®, Ramipril, Bisoprolol, Modified-release Trimetazidine, Emoxicard®, Detraven®, etc.);
- diabetes mellitus (Metformin, Gliclazide, Gliclazide modified release);
- neurological diseases (Spasmaton Neo®, BoriVit®, Soothing drops, Revalon®, Choline alfoscerate);
- gastrointestinal tract (Lansazol®, Ranitidine, Bisacodyl)
- infectious diseases (cephalosporin antibiotics: Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, etc.)
- and others.
The organization's annual production volume is more than 5 billion tablets, 500 million ampoules, 185 million capsules, 50 million bottles of antibiotics in the form of sterile powders, 13 million tubes of ointments and gels, 10 million bottles of tinctures and alcohol solutions.
QUALITY SYSTEM
THE MAIN PRODUCTION SITES OF JSC "BZMP" ARE CERTIFIED FOR COMPLIANCE:
- production requirements of TKP RB 030-2013(02040) “Good Manufacturing Practice (GMP)” (10 certificates);
- manufacturer's statement of conformity ( foreign manufacturer) medicines for medical use according to the requirements of the Rules of Good Manufacturing Practice No. GMP-00075/16/BY, issued by the Ministry of Industry and Trade of the Russian Federation on December 12, 2016;
- production of medicines to GMP requirements of PIC/S member countries (Ukraine), (Certificate No. 088/2015/SAUMP/GMP issued on December 21, 2015);
- production of valerian extract tablets, folic acid in accordance with the requirements of the Regulations of the European Parliament and the Council, issued by the Latvian Certification Center (Certificate No. 0.852/2004 issued on 29.04.2004).
JSC "BZMP" HAS THE FOLLOWING CERTIFIED MANAGEMENT SYSTEMS:
- quality management system for the development and production of medicines and biological active additives complies with the requirements of STB ISO 9001-2009;
- environmental management system for the production and wholesale distribution of medicines (environmental certificate) STB ISO 14001-2005;
- labor protection management system for the development, production of medicines and dietary supplements STB ISO 18001-2009.
(No ratings yet) 
Loading...
